Piramal Pharma Share Price Target 2025, 2030, 2040, 2050

Piramal Pharma is a Pharmaceutical company in West Bengal that generally makes and sells medicine. The company was established in 1988 as part of the Piramal Group. With great effort and hard work, it has become a strong brand today.

What is Piramal Pharma Ltd BOM: 543635?

Piramal Pharma Limited is an Indian company that produces and sells various types of medicines. The company develops and manufactures drugs, sells generic medicines to hospitals, and sells over-the-counter health products in India. Most of its money comes from North America, with the rest coming from Europe, India, Japan, and other countries.

Piramal Pharma Share Price Target Tomorrow

This share gave good returns on the Indian stock market. In the shorter time frame, it falls a bit. So for the shorter trading, you should wait until it shows a bullish moment.

Year	Minimum Price	Maximum Price
2024	-10	+21

Piramal Pharma Share Price Target 2025

Piramal Pharma started in 1984 and has grown worldwide. After separating from Piramal Enterprises, its stock went down a bit. But from the previous year the company recovering very fast. The company reached an all-time high in 2024 and is expected to make much more profit in the upcoming months. By 2025, its share price target would be ₹540 as per our analysis.

As per our analysis, its price will be between ₹150 to ₹540 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	150	540

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	200	277
February	180	300
March	150	250
April	187	267
May	193	273
June	198	280
July	210	308
August	280	380
September	321	430
October	390	478
November	435	510
December	489	540

Piramal Pharma Share Price Target 2026

The Company started in 1984 and has expanded to many overseas countries. The company is valued at approximately Rs 112 billion. After separating from Piramal Enterprises, its stock saw a small drop, but till now the company has broken its all-time high price range. For the long term, it is the best time to invest according to our analysis. It is one of the top CDMO(Contract Development and Manufacturing Organization) companies in the area, with many customers from different parts of the world. In 2026, its share price target would be ₹664 as per our expert’s advice.

In 2026, its price would be between ₹200 to ₹664 according to our expert’s prediction.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	200	664

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	489	540
February	430	467
March	345	380
April	267	288
May	200	256
June	234	293
July	276	367
August	334	390
September	367	473
October	420	560
November	490	610
December	589	664

Share Price Target 2027

It is making big efforts to grow its business in different markets and countries. The company is putting more money into research to create better medicines and healthcare products. By developing a wide range of products and expanding its reach, it is working towards increasing its sales and profits over time. These strategies are likely to help the company become even stronger in the coming years. This makes a good choice for investors who are looking for long-term growth in their investments. In 2027, its share price target would be ₹760 as per our analysis.

Its share price would be between ₹260 to ₹760 in 2027, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	260	760

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	589	681
February	430	490
March	334	374
April	260	310
May	287	387
June	357	432
July	390	478
August	451	520
September	486	590
October	530	631
November	590	690
December	674	760

Share Price Target 2028

The company keep expanding its range of healthcare products and services to reach more people in different countries. It is also working on building partnerships with other companies and buying smaller businesses to help it grow faster.  A large amount of revenue comes from its advanced generic medicines and development of new, innovative healthcare products. These efforts should help the company grow its business and improve its profits. In 2028, its share price target would be ₹870 as per our analysis.

Its share price would be between ₹320 to ₹870 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	320	870

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	674	787
February	530	587
March	430	478
April	456	490
May	470	530
June	488	569
July	521	591
August	568	667
September	623	680
October	654	730
November	680	810
December	790	870

Share Price Target 2029

The company is highly focused on research and development, which means it is always working to create better medicines and improve healthcare solutions. By entering new markets and expanding into different regions, It is likely to reach more customers and grow its business. In addition to R&D, the company is also improving its internal processes, making it more efficient and profitable. These combined efforts are expected to boost the company’s earnings and help its stock price rise significantly over time. In 2029, its share price target would be ₹960 as per our prediction.

By our analysis, its share price would be between ₹390 to ₹960 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	390	960

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	790	889
February	630	671
March	563	589
April	420	472
May	390	490
June	454	556
July	527	587
August	568	680
September	630	768
October	730	835
November	790	897
December	860	960

Piramal Pharma Share Price Target 2030

The company has a strong track record in buying and combining businesses, which will help the company grow and compete in the pharmaceutical market. They do business in the US, Europe, and Japan which helps protect them from relying too much on one place. Also, the company is trying to add more products, improve its operations, and enter new markets. The growth of its complex generics business and more demand for its healthcare products should boost profits. By 2030 its share price target would be ₹1077 as per our prediction.

Its share price will be between ₹450 to ₹1077 by 2030 as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	450	1077

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	860	960
February	735	790
March	624	656
April	537	568
May	450	480
June	460	570
July	530	687
August	642	746
September	705	830
October	787	920
November	887	1023
December	993	1077

Share Price Target 2040

The company focuses of keep inventing effective medicines by inventing a good amount into research and development (R&D). Also, the company is expanding very rapidly by owning small companies and opening new branches which boosts its sales and profits. The company always focus on improving its quality to reach more consumers. By 2040, its share price target would be ₹2560 as per our expert’s analysis.

In 2040, its share price would be between ₹2028 to ₹2560 according to our expert analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	2028	2560

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	2028	2070
February	2046	2120
March	2087	2146
April	2121	2178
May	2146	2215
June	2187	2246
July	2210	2268
August	2246	2290
September	2270	2368
October	2310	2458
November	2417	2490
December	2478	2560

Share Price Target 2050

The company’s focus on innovation and ability to offer high-quality, affordable pharmaceutical products will keep the company one step ahead form its competitors. Also, it partnering with other pharmaceutical companies and buying smaller companies which will strengthen its market position. These strategies could allow the company to expand its products and distribution, which would help increase its share price over time. By 2050, its share price target would be ₹5387 according to the technical analysis and market sentiments.

Its share price would be between ₹4844 to ₹5387 in 2050, as per our deep analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	4844	5387

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	4844	4925
February	4878	4957
March	4890	4990
April	4954	5057
May	5010	5122
June	5078	5178
July	5132	5190
August	5154	5210
September	5178	5230
October	5190	5265
November	5228	5310
December	5287	5387

Should I Buy Piramal Pharma Stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	150	540
2026	200	664
2027	260	760
2028	320	870
2029	390	960
2030	450	1077
2040	2028	2560
2050	4844	5387

The company’s recent financial results show good growth potential. It has seen an increase in revenue and net income, which is a positive sign. It also has a stable profit margin and improved cash flow, which makes it attractive for investors. While it has some debt, its strong revenue and healthy cash reserves help balance this. So overall, it looks like a great option for long-term investors looking for growth and value.

Piramal Pharma Earning Results

Mcap Full (Cr.)	32,513.97
EPS	4.85
CEPS	6.43
ROE	9.16
TTQ (Lakh)	1.90
Turnover (Cr.)	4.67
Face Value	10.00
Cash EPS	1.99
OPM %	27.97
NPM %	16.35
EPS	1.59
Net Profit(Cr.)	210.06
Revenue(Cr.)	1,284.39

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
711.68	4.08	0.05%	50.39	6.41	0.52%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Piramal Pharma Ltd	1,810.36	4.08	0.05%
Sun Pharmaceutical Industries Ltd	46.61	6.65	0.73%
Cipla Ltd	29.17	4.49	0.87%
Torrent Pharmaceuticals Ltd	70.14	16.95	0.82%

Is Piramal Pharma Stock Good to Buy? (Bull case & Bear case)

Bull Case:

• Its revenue and profits increase over time, which is a good sign for the future.
• The pharmaceutical industry is expected to grow more in future.
• The company is spending a lot on research and development.
• With operations in over a hundred countries, it has a diverse market, which reduces risk.
• The company Improves cash flow which helps the company invest and manage its debt better.

Bear Case:

• The company has a lot of debt, which could be risky if profits go down.
• While stable, its profit margin might be lower than some competitors, affecting long-term earnings.
• Depends on launching new products can be problematic if not attract consumers.

Conclusion

For the listing time of this stock, it faced a bearish movement in the stock market because it got separated from the Piramal group but soon it recovered and at the current time it broke its all-time high price level. In this article, we have shared much more information like this which will help you to make a good decision so read the whole article to know about this stock.

FAQs